Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial

2025-521199-80-00 · tracked via the Priya Life Science EU tracker

Sponsor

French Innovative Leukemia Organization

Sponsor type

Laboratory/Research/Testing facility

Therapeutic area

Hemic and Lymphatic Diseases

Decision date

05/11/2025

Enrollment target

Sites

France

Condition studied

Patients with previously untreated symptomatic chronic lymphocytic leukemia.

Investigational medicinal product(s)

PIRTOBRUTINIB

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Peripheral blood with undetectable (<10-4) minimal residual disease at month 24.

Endpoint detail

PB MRD at month 9 and 18 and BM MRD at month 24, Progression free survival (PFS), disease-free survival (DFS), event-free survival (EFS), overall survival (OS) and time to next treatment (TTNT)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521199-80-00 on CTIS ↗ ← All trials in the EU